CD24Fc With Ipilimumab and Nivolumab to Decrease irAE (CINDI)

NCT04060407 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Business Reasons

Conditions

Metastatic Melanoma

Interventions

DRUG: CD24Fc
DRUG: Ipilimumab
DRUG: Nivolumab

Sponsor

Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Collaborators

[object Object]
[object Object]